David S. Hong, MD, on the SURPASS Clinical Trial and TCR T-cell Therapy in Solid Tumors

Video

Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.

“I’m excited about cellular therapy in general in solid tumors... I am really optimistic because I do think that, like in hematologic malignancies, such as lymphoma, it's just a matter of time before we kind of tweaked the technology to have higher efficacy and longer efficacy in these patients who after standard chemo really have no other options.”

Patients with metastatic ovarian, urothelial, gastroesophageal, and head and neck cancers remain without many options when early lines of treatment are not successful. T-cell receptor (TCR) engineered T-cell therapy is being explored as a potential option to address this unmet medical need.

David S. Hong, MD, professor and deputy chair, department of investigational cancer therapeutics, MD Anderson Cancer Center, The University of Texas, recently presented data from the phase 1 SURPASS clinical trial (NCT04044859), which is investigating ADP-A2M4CD8, a CD8+ TCR T-cell therapy, at the 2022 European Society for Medical Oncology (ESMO) Congress, September 9-13, in Paris, France.

In an interview with CGTLive, Hong explained how ADP-A2M4CD8 functions and gave an overview of the study’s findings so far. He also discussed the limitations of the trial and potential avenues for future research. In particular, he mentioned future plans to investigate the therapy in combination with checkpoint inhibitors, and additionally pointed out the need to further investigate means of identifying which patients can benefit from TCR T-cell therapy. He also expressed optimism about the future of cell therapy for the treatment of solid tumors in general.

Click here to read more coverage of ESMO Congress 2022.

Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
© 2024 MJH Life Sciences

All rights reserved.